CD171- and GD2-specific CAR-T cells potently target retinoblastoma cells in preclinical in vitro testing

BACKGROUND: Chimeric antigen receptor (CAR)-based T cell therapy is in early clinical trials to target the neuroectodermal tumor, neuroblastoma. No preclinical or clinical efficacy data are available for retinoblastoma to date. Whereas unilateral intraocular retinoblastoma is cured by enucleation of...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:BMC Cancer
Main Authors: Andersch, Lena, Radke, Josefine, Klaus, Anika, Schwiebert, Silke, Winkler, Annika, Schumann, Elisa, Grunewald, Laura, Zirngibl, Felix, Flemmig, Carina, Jensen, Michael C., Rossig, Claudia, Joussen, Antonia, Henssen, Anton, Eggert, Angelika, Schulte, Johannes H., Künkele, Annette
Formato: Artigo
Idioma:Inglês
Publicado em: BioMed Central 2019
Assuntos:
Research Article
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC6732842/
https://ncbi.nlm.nih.gov/pubmed/31500597
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1186/s12885-019-6131-1
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados